Poseida Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	44.47	81.38	206.33	83.97	87.78	30.4
Short-Term Investments	167.73	201.12	0	225.19	37.53	0
Cash & Cash Equivalents	212.2	282.49	206.33	309.15	125.32	30.4
Cash Growth	-24.88%	36.92%	-33.26%	146.69%	312.30%	-
Receivables	9.01	9.09	0	0	0	0
Other Current Assets	5.26	6.98	7.55	4.84	1.86	2.25
Total Current Assets	226.48	298.56	213.87	314	127.18	32.64
Property, Plant & Equipment	40.78	46.67	48.23	48.32	10.86	3.42
Goodwill and Intangibles	5.55	5.55	5.55	5.55	5.55	5.55
Other Long-Term Assets	1.08	1.06	1.66	3.62	3.41	3.52
Total Long-Term Assets	47.41	53.27	55.44	57.49	19.82	12.48
Total Assets	273.89	351.84	269.31	371.48	147	45.12
Accounts Payable	3.27	2.23	8.96	0.76	4.93	2.86
Deferred Revenue	47.79	41.06	13.76	0	0	0
Current Debt	5.95	5.87	6.34	4.81	3	0
Other Current Liabilities	14.31	4.74	14.28	24.45	13.93	10.17
Total Current Liabilities	71.32	53.89	43.34	30.03	21.86	13.03
Long-Term Debt	79.47	82.89	54.86	54.51	26.14	19.09
Other Long-Term Liabilities	19.39	27.47	14.9	24.98	26.34	17.27
Total Long-Term Liabilities	98.87	110.36	69.76	79.49	52.48	36.35
Total Liabilities	170.18	164.24	113.1	109.52	74.33	49.38
Total Debt	85.42	88.75	61.2	59.32	29.14	19.09
Debt Growth	-3.75%	45.02%	3.17%	103.55%	52.68%	-
Retained Earnings	-594.29	-470.86	-406.86	-281.89	-152.22	-65.69
Comprehensive Income	0.13	-0.15	0	0.01	0.02	0
Shareholders' Equity	103.7	187.6	156.21	261.97	-149.51	-76.72
Net Cash / Debt	126.78	193.74	145.13	249.84	96.18	11.31
Net Cash / Debt Growth	-34.56%	33.50%	-41.91%	159.77%	750.46%	-
Net Cash Per Share	1.41	2.69	2.33	6.94	7.62	0.93
Working Capital	155.16	244.68	170.54	283.97	105.32	19.62
Book Value Per Share	1.15	2.61	2.51	7.28	-11.85	-6.30

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).